Grifols Therapeutics LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$26.2M
Doctors Paid
25
Transactions
3,122
2024 Total
$1.1M
Payment Breakdown by Category
Research$26.2M (99.9%)
Consulting$17,350 (0.1%)
Travel$15,380 (0.1%)
Food & Beverage$3,690 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26.2M | 3,042 | 99.9% |
| Consulting Fee | $17,350 | 8 | 0.1% |
| Travel and Lodging | $15,380 | 49 | 0.1% |
| Food and Beverage | $3,690 | 23 | 0.0% |
Payments by Type
Research
$26.2M
3,042 transactions
General
$36,420
80 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass | $3.1M | 0 | 404 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens 60 mgkg and 120 mgkg of Weekly Intravenous Alpha1 Proteinase Inhibitor Human in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin D | $2.8M | 0 | 567 |
| A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin IVIG Plus Standard Medical Treatment SMT Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the In | $2.7M | 0 | 100 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency | $2.4M | 0 | 146 |
| Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | $2.0M | 0 | 260 |
| Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein 5 in Patients With Amyotrophic Lateral Sclerosis | $1.8M | 0 | 74 |
| Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure ACLF at High Risk of Hospital Mortality | $1.6M | 0 | 155 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor Human, Modified Process 60 mgkg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency | $1.4M | 0 | 277 |
| A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency | $1.2M | 1 | 122 |
| A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus HAV Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects | $1.1M | 0 | 49 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | $954,409 | 0 | 123 |
| An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20 Administered for 6 Months in Subjects With Primary Immunodeficiency | $747,262 | 1 | 134 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With 'Acute-On-Chronic Liver Failure' (ACLF) at High Risk of Hospital Mortality | $592,094 | 0 | 57 |
| A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG compared to Gamunex-C in Subjects with Primary Humoral Immunodeficiency | $587,201 | 0 | 25 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin Human, 10 CaprylateChromatography Purified IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | $521,668 | 0 | 97 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality. | $490,547 | 0 | 65 |
| A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus | $477,236 | 0 | 106 |
| A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency | $417,488 | 0 | 52 |
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor Human Plus Standard Medical Treatment SMT Versus Placebo Plus SMT in Hospitalized Subjects With | $291,394 | 0 | 53 |
| An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20percent Administered for 6 Months in Subjects With Primary Immunodeficiency | $108,538 | 1 | 23 |
| A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Subjects with COVID-19 Requiring Admission to the Intensive Care Unit | $96,042 | 0 | 20 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | $78,917 | 0 | 5 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | $78,668 | 0 | 11 |
| A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma Derived Factor VIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A | $60,535 | 0 | 9 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFYplus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | $58,980 | 0 | 12 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency | $53,497 | 0 | 8 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel?Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome | $51,189 | 0 | 12 |
| A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects with Primary Immunodeficiency | $50,828 | 0 | 3 |
| A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of PlasmaDerived Factor VIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A | $41,401 | 0 | 11 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency | $41,277 | 0 | 13 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Specialist | $149,344 | 1 | $149,344 |
| Gastroenterology | $9,587 | 7 | $1,370 |
| Critical Care Medicine | $4,664 | 1 | $4,664 |
| Internal Medicine | $4,368 | 3 | $1,456 |
| Hematology & Oncology | $2,700 | 1 | $2,700 |
| Blood Banking & Transfusion Medicine | $2,473 | 1 | $2,473 |
| Anesthesiology | $2,277 | 2 | $1,139 |
| Hepatology | $2,050 | 1 | $2,050 |
| Clinical & Laboratory Immunology | $1,400 | 1 | $1,400 |
| Surgery | $1,372 | 1 | $1,372 |
| Pediatric Surgery | $1,323 | 1 | $1,323 |
| Student in an Organized Health Care Education/Training Program | $1,262 | 1 | $1,262 |
| Plastic Surgery | $1,196 | 1 | $1,196 |
| Nephrology | $246.09 | 2 | $123.05 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. William Lumry, M.d, M.D | Specialist | Dallas, TX | $149,344 | $0 |
| Ram Subramanian, M.d, M.D | Critical Care Medicine | Atlanta, GA | $4,664 | $0 |
| Dr. Jacqueline O'leary, Md, Mph, MD, MPH | Gastroenterology | Dallas, TX | $4,263 | $0 |
| Dr. Brian Hill, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Cleveland, OH | $2,700 | $0 |
| Dr. Zbigniew Szczepiorkowski, Md, Phd, MD, PHD | Blood Banking & Transfusion Medicine | Lebanon, NH | $2,473 | $0 |
| Dr. Arun Jesudian, Md, MD | Internal Medicine | New York, NY | $2,050 | $0 |
| Shivang Mehta, M.d, M.D | Internal Medicine | Fort Worth, TX | $2,050 | $0 |
| Prof. Tarek Hassanein, M.d, M.D | Hepatology | Coronado, CA | $2,050 | $0 |
| Joshua Turkeltaub, M.d, M.D | Gastroenterology | Miami, FL | $1,650 | $0 |
| Unknown Provider | — | — | $1,501 | $0 |
| Stephen Dreskin, Md, MD | Clinical & Laboratory Immunology | Aurora, CO | $1,400 | $0 |
| Harold Minkowitz, M.d, M.D | Anesthesiology | Houston, TX | $1,374 | $0 |
| Dr. Dev Desai, M.d, M.D | Surgery | Phoenix, AZ | $1,372 | $0 |
| Dr. Alexander Feliz, Md, MD | Pediatric Surgery | Memphis, TN | $1,323 | $0 |
| Dr. Andrew Stec, Md, MD | Student in an Organized Health Care Education/Training Program | Charleston, SC | $1,262 | $0 |
| Brooke Burkey, M.d, M.D | Plastic Surgery | Philadelphia, PA | $1,196 | $0 |
| Dr. David Leiman, M.d, M.D | Anesthesiology | Houston, TX | $903.80 | $0 |
| Ravi Vora, Md, MD | Gastroenterology | Atlanta, GA | $805.89 | $0 |
| Sonal Kumar, Md, MD | Gastroenterology | New York, NY | $745.60 | $0 |
| Ethan Weinberg | Gastroenterology | Philadelphia, PA | $722.92 | $0 |
| Mary Flynn, M.d, M.D | Gastroenterology | Worcester, MA | $721.96 | $0 |
| Dr. Jasmohan Bajaj, Md, MD | Gastroenterology | Richmond, VA | $677.68 | $0 |
| Kuchikula Reddy, Md, MD | Internal Medicine | Philadelphia, PA | $267.91 | $0 |
| John Videen, Md, MD | Nephrology | Chula Vista, CA | $143.19 | $0 |
| Nilang Patel, M.d, M.D | Nephrology | Richmond, VA | $102.90 | $0 |
Ad
Top Products
- Albutein $7.2M
- Gamunex-C $6.4M
Associated Products (4)
- Albutein $12.0M
- Gamunex-C $11.4M
- Prolastin-C $7.2M
- GamaSTAN SD $1.1M
Payment Categories
- Food & Beverage $3,690
- Consulting $17,350
- Travel & Lodging $15,380
- Research $26.2M
About Grifols Therapeutics LLC
Grifols Therapeutics LLC has made $26.2M in payments to 25 healthcare providers, recorded across 3,122 transactions in the CMS Open Payments database. In 2024, the company paid $1.1M. The top product by payment volume is Albutein ($7.2M).
Payments were distributed across 14 medical specialties. The top specialty by payment amount is Specialist ($149,344 to 1 doctors).
Payment categories include: Food & Beverage ($3,690), Consulting ($17,350), Research ($26.2M), Travel & Lodging ($15,380).
Grifols Therapeutics LLC is associated with 4 products in the CMS Open Payments database, including Albutein, Gamunex-C, and Prolastin-C.